First Nasal Self-Administered Flu Vaccine Approved by FDA
The first influenza nasal spray vaccine that can be self-administered has been approved by the U.S. Food and Drug Administration (FDA).
Nasal COVID-19 Vaccine Halts Transmission of SARS-CoV-2
A study by researchers at Washington University School of Medicine in St. Louis indicates next-generation vaccines that target a virus’s points of entry — the nose and mouth — may be able to contain the spread of respiratory infections and prevent transmission.
Increasing Vaccine Development Provides Hope, Despite Resistance
It’s alarming that despite vaccines’ proven success, some 40,000 to 50,000 adults die from vaccine-preventable diseases each year. Even diseases that were once-eradicated are making a comeback.
COVID Vaccines: What’s Available Now and What’s in the Works?
Three top vaccine producers are making newer vaccines that not only protect against the newer sublineages of COVID-19, but that also protect against other respiratory viruses.
Viruses, Variants and Vaccines: Staying Ahead of the Spread
Although history has proven the success of vaccines in controlling the spread of diseases, emerging threats are concerning. However, hope is on the horizon with studies of newer vaccines.
Study Shows Vaccination Decision in IEI Patients Must Be Individualized
Inborn errors of immunity (IEI) increase morbidity and mortality risks, particularly from respiratory tract infections. Hence, vaccination becomes pivotal for IEI patients.
The Protective Value of RSV Vaccines in Older Adults: A Deeper Dive
Now that safe and effective RSV vaccines are finally available, more evidence of their direct health benefits in older Americans will be forthcoming. It is likely as well that FDA will eventually expand the marketing approvals of these vaccines to include adults under age 60 with chronic conditions demonstrated to importantly increase the risk of RSV-associated LRTD and hospitalization.
New Study to Examine COVID-19 Vaccines in People with Weakened Immune Systems
Researchers at the University of Wisconsin (UW) School of Medicine and Public Health are exploring the ideal vaccine booster strategy for immunosuppressed patients to protect those at higher risk of severe illness and complications from COVID-19 infection.
New Vaccine Could Lower ‘Bad’ Cholesterol by as Much as 30 Percent
A new vaccine currently in development can effectively and affordably lower levels of “bad’ cholesterol in the body, a health problem that affects almost two in five adults in the U.S.
The Anti-Vaccine Movement: Where Are We Now?
Despite scientific evidence to the contrary, doubts about vaccine safety and efficacy have not only persisted, but escalated. Counteracting this wave of mistrust will require targeted tactics and networked, community involvement.
